Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Rezolute, Inc. ( Rezolute , the Company , we or us ) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism ( HI ). Summary of Clinical Assets Ersodetug Our lead clinical asset, ersodetug, is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism.
$3.84
$0.11 (-2.78%)
EOD Sep 18, 2026
Negative free cash flow of -$69M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$81M
▼ -8.7% YoY
Op. Margin
—
ROIC
-49.27%
▲ +2.0pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$73M
▼ -20.4% YoY
Op. Cash Flow (TTM)
-$73M
▼ -20.4% YoY
Net Debt
-$119M
Net Cash Position
Cash & Equiv.
$120M
Continue Research
SourceComputed from the 10-Q filed 12 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 13 May 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Jun. Sector medians are approximate S&P 500 benchmarks and update periodically.